ACE inhibitors

A class of medicines whose main uses are treating high blood pressure and heart failure. MeSH says they work mainly by inhibiting the renin-angiotensin system, and cause mostly widening of blood vessels and a mild loss of salt in the urine without changing the heart rate. The US label read for one ACE inhibitor also lists lowering the risk of death when treatment starts within 24 hours of a heart attack in people whose circulation is stable, and carries a boxed warning that these drugs can cause injury and death to the developing fetus.

Also called ACE inhibitor · Angiotensin-converting enzyme inhibitors

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH descriptor D000806 (Angiotensin-Converting Enzyme Inhibitors, last updated 2026-01-01) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name lisinopril tablet (application NDA019777, effective 2025-01-02 in openFDA). It calls the medicine an ACE inhibitor and lists hypertension (adults and pediatric patients 6 years of age and older), adjunct therapy for heart failure and reduction of mortality in a window after acute myocardial infarction. A separate claim records its boxed warning on fetal toxicity; the recipient of that risk is the fetus. One label stands for one product, so other members of the class may list other uses, and no other label was read. This page gives no dose, no trial result and no guideline statement. Medicines of the class that have their own pages are filed under it.

Trials at a glance

The figures count the 1 registry trial in this atlas that names this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
1
Phase 3 or 4
1
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseSuspendedAll statuses
Phase 411
All phases11

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

Drugs in this class

3 drugs in this atlas are filed under ACE inhibitors, with the registry trials and FDA regulatory decisions this atlas holds for each. With ACE inhibitors itself, the class has 27 distinct trials and 33 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
MeSH says these drugs exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. A US label explains that the enzyme they block converts angiotensin I to the vasoconstrictor angiotensin II.

Claims and evidence

Context People with hypertension (adults and pediatric patients 6 years and older), heart failure or a recent heart attack, as described in the US label of an ACE inhibitor

Recipient
Mixed recipients
Population
Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with systolic heart failure, and hemodynamically stable patients within 24 hours of acute myocardial infarction.
Care setting
Prescription medicine, as described in the US label
Geography
United States (US drug label)
Life stage
Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
  • Adults and pediatric patients 6 years of age and older with hypertension
  • Systolic heart failure (adjunct therapy)
  • Hemodynamically stable patients within 24 hours of acute myocardial infarction
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ZESTRIL (lisinopril tablets, Upsher-Smith Laboratories, application NDA019777; the version dated 2025-01-02 in openFDA) calls the medicine an angiotensin converting enzyme (ACE) inhibitor. It lists treating hypertension in adults and pediatric patients 6 years of age and older, adjunct therapy for heart failure (its detailed text says to reduce signs and symptoms of systolic heart failure), and reducing mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction. MeSH describes the class in the same terms, as drugs whose main indications are the treatment of hypertension and heart failure.

    Applies to Mixed recipients People with hypertension (adults and pediatric patients 6 years and older), heart failure or a recent heart attack, as described in the US label of an ACE inhibitor

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Other ACE inhibitor labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that calls the medicine an ACE inhibitor and the hypertension, heart failure (systolic heart failure in section 1.2) and acute myocardial infarction uses.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports MeSH scope note for descriptor D000806 (Angiotensin-Converting Enzyme Inhibitors)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0001207 of descriptor D000806, fetched 2026-10-25. The scope note is on this concept record, not on the descriptor record. · MeSH: M0001207

      Locator
      scopeNote.@value
      How it applies
      MeSH scope note: main indications of the class.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      e0f6d57f67dfdc38977aa3de8fe4fc3ea23b840a72635886b2966506da249e97
      Reuse basis
      The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-10-25 and may not reflect the most current data. The raw bytes are committed in the atlas repository.

Context The developing fetus, for a person taking an ACE inhibitor during pregnancy, as described in a US label boxed warning

Recipient
Fetal
Population
The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
Care setting
Prescription medicine, as described in the US label
Geography
United States (US drug label)
Life stage
Fetus during pregnancy; the passage read gives no gestational ages
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Pregnancy during which the medicine is taken (risk to the fetus)
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of ZESTRIL carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.

    Applies to Fetal The developing fetus, for a person taking an ACE inhibitor during pregnancy, as described in a US label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0]
      How it applies
      The boxed warning title and its fetal-injury statement.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In pregnancy 1

Claims whose context is a pregnancy or a fetus.

  • Safety Evidence stage not applicable Certainty not assessed

    The same US label of ZESTRIL carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.

    Applies to Fetal The developing fetus, for a person taking an ACE inhibitor during pregnancy, as described in a US label boxed warning

    Population, setting and follow-up
    • The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
    • Prescription medicine, as described in the US label
    • United States (US drug label)
    • Fetus during pregnancy; the passage read gives no gestational ages
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0]
      How it applies
      The boxed warning title and its fetal-injury statement.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250102.
      Retrieved
      Source effective date
      2025-01-02
      Source state
      Current
      Version fingerprint
      19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry trials 1

Record details

Record id
cardio:ace-inhibitors
Content hash
2a216bbdb6c4bbc95eaccf86fd2a28bfc83992fc469a4dcc9ff33e2b28ece90e